SRPK1 and Denys-Drash syndrome: Indeed, WT1 repressed SRPK1 transcription in a non‐tumoral Denys Drash Syndrome podocyte cell line [58], whereas a more recent study reported that WT1 acts as a transcriptional activator of SRPK1 in prostate cancer and leukaemia cells [59].